2012 Fiscal Year Final Research Report
Innovative Asymmetris Synthesis of Pharmaceuticals Through Strategic Development of Multifunctional and Multimetallic Catalysts
| Project/Area Number |
20229001
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (S)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Chemical pharmacy
|
|---|
| Research Institution | Microbial Chemistry Research Foundation (2011-2012)
The University of Tokyo (2008-2010) |
|---|
Principal Investigator |
SHIBASAKI Masakatsu 公益財団法人微生物化学研究会, 微生物化学研究所, 所長 (30112767)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUMAGAI Naoya 公益財団法人微生物化学研究会, 微生物化学研究所, 主任研究員 (40431887)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KANAI Motomu 東京大学, 大学院・薬学系研究科, 准教授 (20243264)
MATSUNAGA Shigeki 東京大学, 大学院・薬学系研究科, 講師 (50334339)
|
|---|
| Project Period (FY) |
2008 – 2012
|
| Keywords | 不斉触媒 / 不斉合成 / 原子効率 / 医薬合成 / 環境調和型合成 |
|---|
| Research Abstract |
The aim of this research project is rational design and development of cooperative multimetallic catalysts based on detailed mechanistic analysis, and their application to the enantioselective synthesis of therapeutics. A number of novel catalytic asymmetric reactions have been revealed through the identification of new multimetallic catalysts based on three different chiral ligand platforms. The synthetic utility of these catalysts culminated in the enantioselective synthesis of phamaceuticals including tamiflu, relenza, and lipitor.
|
